Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 22;8:434. doi: 10.1038/s41392-023-01653-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — The correlation between tumor-infiltrating γδ T cells and cancer pathogenesis, along with the clinical potential of allogeneic γδ T cells in tumor immunotherapy. According to our recent TCGA-based bioinformatics analysis (a–c) and revisiting our previous clinical trial data records (d),^11,12 allogeneic γδ T cell indicates the future of tumor immunotherapy. a The abundance of γδ T cells in normal and tumor tissue depends on the type of organ (‘n’ represents normal). b Correlation analysis between TRDC and programmed cell death (PCD) gene sets show variability across cancers. Nevertheless, pyroptosis and PANoptosis of γδ T cells appear to be more correlated with cancers than other PCD pathways. PCD gene set lists are provided in the supplemental file. The correlation coefficient is represented by “r”. c The infiltrated γδ T cells (TRDC) can serve as an indicator for the overall survival (OS) in a very small fraction of cancer types (11/33), and only correlate with better OS in 9/33 cancers. d Our clinical trials have shown that allogeneic Vδ2 T therapy significantly increases the percentages of CD4⁺ and CD8⁺ T cells in certain patients with solid tumors (represented by red lines in the graph, each line representing data from an individual patient). e A sketch graph of allogeneic γδ T cell-based cancer immunotherapy is presented, along with potential challenges and γδ T^plus strategy (γδ T + mAb, bispecific Ab, chemo, radio, intervention, etc.) in clinical application. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. ACC Adrenocortical carcinoma, BLCA Bladder Urothelial Carcinoma, BRCA Breast invasive carcinoma, CESC Cervical squamous cell carcinoma, CHOL Cholangio carcinoma, COAD Colon adenocarcinoma, DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, ESCA Esophageal squamous cell carcinoma, GBM Glioblastoma multiforme, HNSC Head and neck squamous cell carcinoma, KICH Kidney chromophobe, KIRC Kidney renal clear cell carcinoma, KIRP Kidney renal papillary cell carcinoma, LAML Acute myeloid leukemia, LGG Brain lower grade glioma, LIHC Liver hepatocellular carcinoma, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma, MESO Mesothelioma, OV Ovarian serous cystadenocarcinoma, PAAD Pancreatic adenocarcinoma, PCPG Pheochromocytoma and paraganglioma, PRAD Prostate adenocarcinoma, READ Rectum adenocarcinoma, SARC Sarcoma, SKCM Skin cutaneous melanoma, STAD Stomach adenocarcinoma, TGCT Testicular germ cell tumors, THCA Thyroid carcinoma, THYM Thymoma, UCEC Uterine corpus endometrial carcinoma, UCS Uterine carcinosarcoma, UVM Uveal melanoma